
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc. demonstrates a positive outlook due to the potential for early intervention in neurodegenerative diseases, as indicated by its amended protocol for PBFT02, which aims to maximize treatment benefits by aligning closer to registrational trial standards. The company has reported encouraging data from its June 2025 interim upliFT-D trial, showcasing a sustained mean increase in CSF PGRN levels, suggesting effective therapeutic impact over 18 months. Additionally, the prospect of accelerated regulatory approval based on biomarker endpoints could shorten trial timelines and enhance Passage Bio's market positioning, especially if its performance aligns favorably with competitors in similar stages of development.
Bears say
Passage Bio Inc. operates in a high-risk sector, focusing on gene therapy for rare CNS disorders, and is currently facing significant challenges that contribute to a negative financial outlook. Key concerns include potential delays in clinical timelines for its pipeline products, PBGM01 and PBFT02, which could be exacerbated by unforeseen safety signals and regulatory hurdles, ultimately affecting market sentiment and revenue forecasts. Additionally, the company may encounter constraints related to manufacturing capacity, which could further hinder its ability to deliver on growth expectations in the competitive gene therapy landscape.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares